About: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article (publication date: 9 August 2008)

Attributes	Values
rdf:type	Item
description	artículu científicu espublizáu en 2008 (ast) ശാസ്ത്രപ്രബന്ധം (ml) 2008 թվականի օգոստոսին հրատարակված գիտական հոդված (hy) наукова стаття, опублікована в серпні 2008 (uk) 2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած (hyw) wetenschappelijk artikel (gepubliceerd op 2008/08/09) (nl) مقالة علمية (نشرت في 9-8-2008) (ar) im August 2008 veröffentlichter wissenschaftlicher Artikel (de) article publié dans la revue scientifique The Lancet (fr) scientific article (publication date: 9 August 2008) (en)
publication date	wds:Q29618031-7C5F5255-9BE6-4B0A-9708-584F5005A371
publication date	2008-07-22 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q29618031-1B4B44F6-5962-48A2-86E5-596763C06C07
language of work or name	English
cites work	wds:Q29618031-08965A80-823A-4336-8E5A-C9ACD1EF164B wds:Q29618031-1E13B19C-93B7-4DE2-B837-555F734346A0 wds:Q29618031-26B1F5AF-1D29-4A1D-B56D-466744788E6B wds:Q29618031-2B7D789A-7575-4EBF-B3A8-936973798112 wds:Q29618031-2FDA307E-3B0A-434C-8C2E-89F89657752C wds:Q29618031-303EDAA7-FB5B-4EE0-A56E-7A5B179260DD wds:Q29618031-6D7441D0-CCE5-439A-8B88-2241D22858C0 wds:Q29618031-7624C4F4-DA73-41DD-BA79-D28C00BEC309 wds:Q29618031-8B1BB115-29A9-4EC4-9D0E-51D9514E22F2 wds:Q29618031-965AC52D-0816-4A91-AFB3-B080C10ED71C wds:Q29618031-9F71C5AE-BFA9-43C0-8497-8D2D57C521B5 wds:Q29618031-A462BCCD-F6FD-45DD-993B-14BDC37896A8 wds:Q29618031-A935CFF0-501A-4F78-985E-7BE38207327E wds:Q29618031-B07C74E0-7B32-4DE3-995E-DEF2621C24EA wds:Q29618031-C34B018D-9B2E-4141-A322-8A8954F036CC wds:Q29618031-CDB1F83C-1CC5-403B-A7B5-17137FA2FE56 wds:Q29618031-DA8E81C0-94DA-4A60-997E-09BB249BD6EB wds:Q29618031-DC363DA4-C1A2-422D-B1D4-94E36511AD6A wds:Q29618031-E2337BCF-E3F0-4A47-8520-0F8F9D7279A9 wds:Q29618031-E89E7058-6A7F-42A2-ADA1-8038DDFD4CE0 wds:Q29618031-FC3BB800-516B-4DBD-A78F-A05AA894D59B
cites work	Immunotherapy for advanced renal cell cancer Targeted therapy for advanced renal cell carcinoma A Multiple Testing Procedure for Clinical Trials The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma Renal-cell carcinoma--molecular pathways and therapies. Renal-cell carcinoma The von Hippel-Lindau tumor suppressor gene and kidney cancer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada Sunitinib versus interferon alfa in metastatic renal-cell carcinoma Sorafenib in advanced clear-cell renal-cell carcinoma Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial TSC2 regulates VEGF through mTOR-dependent and -independent pathways End points and United States Food and Drug Administration approval of oncology drugs Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma Development and validation of a scale to measure disease-related symptoms of kidney cancer
author name string	wds:Q29618031-1561E85C-E634-40BA-9B76-C7047AEB7431 wds:Q29618031-2E55178D-1F6B-4AC2-A564-0F3FB601D831 wds:Q29618031-3C22A0A8-583D-4A52-94ED-F3548F800F0B wds:Q29618031-5F3E135C-A471-4480-A0F0-648148186D57 wds:Q29618031-7AA8D29C-92A5-4099-87FF-E91BFCEFDBC4 wds:Q29618031-80774CFD-7FC7-4841-867C-263F369B2D11 wds:Q29618031-87775F58-3A03-4AAA-8450-C834832E2CE3 wds:Q29618031-A54AB6A7-82C3-4341-9B36-002712EE674D wds:Q29618031-B8409397-8AFE-4FB2-AA74-4A2483674468 wds:Q29618031-D75CF5EB-5251-41E3-B745-65F330437177 wds:Q29618031-E7EA02F4-568C-4312-9735-3DA408A86184 wds:Q29618031-F60EA8A6-1641-4C87-9BDC-6A08AF608958 wds:Q29618031-F72EAF8B-DF32-4979-845F-C4F52B489D57
OpenCitations bibliographic resource ID	wds:Q29618031-3D3A88D4-4D3A-4BA0-B8F2-DA576146B650
OpenCitations bibliographic resource ID	https://w3id.org/oc/corpus/br/19195
author name string	Thomas E Hutson Andrea Kay Stéphane Oudard John A Thompson Robert A Figlin Bernard Escudier Sergio Bracarda David Lebwohl Viktor Grünwald William J Berg Norbert Hollaender Gladys Urbanowitz RECORD-1 Study Group
OpenCitations bibliographic resource ID	19195
rdfs:label	Eficacia de everolimus en el carcinoma avanzado de células renales: ensayo de fase III, doble ciego, aleatorizado y controlado con placebo (es) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (en) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (ast)
skos:prefLabel	Eficacia de everolimus en el carcinoma avanzado de células renales: ensayo de fase III, doble ciego, aleatorizado y controlado con placebo (es) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (en) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (ast)
name	Eficacia de everolimus en el carcinoma avanzado de células renales: ensayo de fase III, doble ciego, aleatorizado y controlado con placebo (es) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (en) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (ast)
author	wds:Q29618031-1DBC9DEB-3AEF-4813-982A-324DD78AE8CD wds:Q29618031-F666FD90-5531-4D1D-84DD-985C82E99A48 wds:Q29618031-FB98785D-CE6C-4ED9-A7D0-CE126D4BFE7B
author	Alain Ravaud Camillo Porta

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software